Onc Now | Episode 25
In this episode, Sara Tolaney focuses on advancing breast cancer treatment through innovative clinical research. She has been instrumental in developing novel therapies and leading key clinical trials, particularly for early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Sara Tolaney
Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School, Boston, Massachusetts, USA. Tolaney has focused on advancing breast cancer treatment through innovative clinical research. She has been instrumental in developing novel therapies and leading key clinical trials, particularly for early-stage HER2-positive breast cancer.
Timestamps
00:09 – Introduction
01:12 – What is HER2-positive breast cancer?
03:00 – Key trials Tolaney has led
07:16 – Antibody-drug conjugates
12:00 – Breast Oncology Guidelines
14:51 – Treatment optimisation
18:27 – Equity in healthcare
21:10 – Mentoring the next generation of oncologists
22:52 – Tolaney’s wishes for healthcare
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ
